Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Merck
Medtronic
AstraZeneca
McKinsey

Last Updated: September 30, 2022

TAUVID Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Tauvid, and when can generic versions of Tauvid launch?

Tauvid is a drug marketed by Avid Radiopharms Inc and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-six patent family members in sixteen countries.

The generic ingredient in TAUVID is flortaucipir f-18. One supplier is listed for this compound. Additional details are available on the flortaucipir f-18 profile page.

DrugPatentWatch® Generic Entry Outlook for Tauvid

Tauvid will be eligible for patent challenges on May 28, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 19, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for TAUVID
International Patents:26
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 2
Clinical Trials: 9
Patent Applications: 10
What excipients (inactive ingredients) are in TAUVID?TAUVID excipients list
DailyMed Link:TAUVID at DailyMed
Drug patent expirations by year for TAUVID
DrugPatentWatch® Estimated Generic Entry Opportunity Date for TAUVID
Generic Entry Date for TAUVID*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TAUVID

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The Cleveland ClinicPhase 1
Avid RadiopharmaceuticalsPhase 2
Avid RadiopharmaceuticalsPhase 1

See all TAUVID clinical trials

US Patents and Regulatory Information for TAUVID

TAUVID is protected by one US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of TAUVID is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting TAUVID

Imaging agents for detecting neurological dysfunction
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

FDA Regulatory Exclusivity protecting TAUVID

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Avid Radiopharms Inc TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123-001 May 28, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Avid Radiopharms Inc TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123-002 May 28, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Avid Radiopharms Inc TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123-001 May 28, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Avid Radiopharms Inc TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123-002 May 28, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for TAUVID

When does loss-of-exclusivity occur for TAUVID?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 12381042
Estimated Expiration: See Plans and Pricing

Canada

Patent: 15390
Estimated Expiration: See Plans and Pricing

Patent: 73963
Estimated Expiration: See Plans and Pricing

China

Patent: 4781234
Estimated Expiration: See Plans and Pricing

Patent: 7011342
Estimated Expiration: See Plans and Pricing

Colombia

Patent: 31359
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0220401
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 47558
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 47558
Estimated Expiration: See Plans and Pricing

Patent: 99763
Estimated Expiration: See Plans and Pricing

Patent: 52572
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 58352
Estimated Expiration: See Plans and Pricing

Japan

Patent: 76206
Estimated Expiration: See Plans and Pricing

Patent: 11512354
Estimated Expiration: See Plans and Pricing

Patent: 15517572
Estimated Expiration: See Plans and Pricing

Lithuania

Patent: 47558
Estimated Expiration: See Plans and Pricing

Poland

Patent: 47558
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 47558
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 47558
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1609504
Estimated Expiration: See Plans and Pricing

Patent: 100135235
Estimated Expiration: See Plans and Pricing

Patent: 150002854
Estimated Expiration: See Plans and Pricing

Spain

Patent: 92830
Estimated Expiration: See Plans and Pricing

Patent: 07992
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TAUVID around the world.

Country Patent Number Title Estimated Expiration
Poland 2247558 See Plans and Pricing
Spain 2792830 See Plans and Pricing
Colombia 7131359 Agentes de imagen para detectar disfunci├│n neurol├│gica See Plans and Pricing
Denmark 2247558 See Plans and Pricing
South Korea 20100135235 NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION See Plans and Pricing
Australia 2012381042 Carboline and carbazole based imaging agents for detecting neurological dysfunction See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Johnson and Johnson
McKinsey
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.